Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Satellite Stem Cells and Muscular Dystrophy

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ndfip2 in TrkA-expressing sensory neurons regulates noxious mechanosensation through control of TrkA signaling and protein levels.

Cell death & disease·2026

Same author

Constitutive neuronal expression and disease-associated upregulation of chitinases in amyotrophic lateral sclerosis.

Brain : a journal of neurology·2026

Same author

Vascular and Neural Transcriptomics Reveal Stage-Dependent Pathways to Inflammation and Cognitive Dysfunction in a Rat Model of Hypertension.

Journal of the American Heart Association·2025

Same author

Retinal degeneration driven by brain-derived neurotrophic factor deficiency in microglia and T-lymphocytes.

Scientific reports·2025

Same author

Munc13-1 restoration mitigates presynaptic pathology in spinal muscular atrophy.

Nature communications·2025

Same author

Loss of synaptic Munc13-1 underlies neurotransmission abnormalities in spinal muscular atrophy.

Cellular and molecular life sciences : CMLS·2025

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Published on: October 3, 2011

Therapy development in spinal muscular atrophy.

Michael Sendtner¹

¹Institute for Clinical Neurobiology, University of Wuerzburg, Wuerzburg, Germany. sendtner_m@klinik.uni-wuerzburg.de

Nature Neuroscience

|June 29, 2010

Summary

This summary is machine-generated.

Spinal muscular atrophy (SMA) is a motor neuron disease caused by low survival motor neuron (SMN) protein. Advances in stem cells and oligonucleotide therapies show promise for treating SMA and other neurodegenerative disorders.

More Related Videos

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations

Published on: February 2, 2024

Related Experiment Videos

Last Updated: Jun 11, 2026

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Delivery of Therapeutic Agents Through Intracerebroventricular (ICV) and Intravenous (IV) Injection in Mice

Published on: October 3, 2011

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Repeated Transcranial Magnetic Stimulation Combined with Action Observation Training in Children with Spastic Cerebral Palsy

Published on: August 9, 2024

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations

Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations

Published on: February 2, 2024

Area of Science:

Neuroscience
Genetics
Biochemistry

Background:

Proximal spinal muscular atrophy (SMA) is a common childhood motor neuron disease.
SMA results from deficiency of the survival motor neuron (SMN) protein, caused by a homozygous autosomal recessive genetic defect.
Current therapies aim to increase SMN protein levels from the SMN2 gene, but underlying disease mechanisms require further elucidation.

Purpose of the Study:

To review the current state of therapeutic development for SMA.
To highlight the potential of human induced pluripotent stem cells (hiPSCs) for drug screening.
To discuss the progress and challenges in oligonucleotide-based therapies targeting SMN2 splicing.

Main Methods:

Review of existing literature on SMA pathogenesis and therapeutic strategies.
Discussion of the utility of mouse models and the potential of hiPSC-derived motor neurons for drug discovery.
Analysis of advancements in oligonucleotide technology for modulating SMN2 pre-mRNA splicing.

Main Results:

Mouse models have advanced understanding of SMA but require validation for therapeutic screening.
Human induced pluripotent stem cell technology offers a scalable platform for generating human motor neurons for drug screening.
Oligonucleotide-based approaches to correct SMN2 splicing are nearing clinical trials.

Conclusions:

Overcoming drug delivery challenges is crucial for the success of oligonucleotide therapies for SMA.
Advancements in hiPSC technology and oligonucleotide therapeutics hold significant potential for SMA treatment.
Successful therapeutic strategies for SMA could inform treatments for other neurodegenerative diseases.